Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm

• Status: Completed
• Trial end date: 2011-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of Meditoxin® in the treatment of Essential blepharospasm.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medy-Tox
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A; incobotulinumtoxinA; onabotulinumtoxinA

Criteria

Inclusion Criteria:

• Men and women aged above 18

• Subjects who was diagnosed with Essential Blepharospasm

• Subjects who voluntarily Signed written informed consent

• Subjects who can adhere to protocol and study requirements

Exclusion Criteria:

• Subjects with known history of allergy considered due to Botulinum toxin type A

• Subjects who have received botulinum toxin A type within 3 months

• Any disease that might affect neuromuscular function (e.g.. Myasthenia Gravis, Lambert-Eaton Syndrome, Amyotrophic Lateral Sclerosis ect.)

• Subjects who are participating in other clinical trials

• Pregnant or lactating female Subjects

• Subjects who are not eligible for the study at the discretion of the Investigator.